Jeff Yass’s Myovant Sciences Ltd. MYOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-25,615
| Closed | -$691K | – | 14055 |
|
|
2022
Q4 | $691K | Sell |
25,615
-345,550
| -93% | -$9.09M | ﹤0.01% | 7055 |
|
|
2022
Q3 | $6.67M | Buy |
371,165
+112,135
| +43% | +$1.79M | ﹤0.01% | 2724 |
|
|
2022
Q2 | $3.22M | Sell |
259,030
-232,654
| -47% | -$2.57M | ﹤0.01% | 3943 |
|
|
2022
Q1 | $6.55M | Sell |
491,684
-103,010
| -17% | -$1.38M | ﹤0.01% | 3200 |
|
|
2021
Q4 | $9.26M | Buy |
594,694
+437,449
| +278% | +$8.35M | ﹤0.01% | 2831 |
|
|
2021
Q3 | $3.53M | Sell |
157,245
-75,222
| -32% | -$1.65M | ﹤0.01% | 4609 |
|
|
2021
Q2 | $5.29M | Sell |
232,467
-57,015
| -20% | -$1.2M | ﹤0.01% | 3938 |
|
|
2021
Q1 | $5.96M | Buy |
289,482
+63,928
| +28% | +$1.46M | ﹤0.01% | 3584 |
|
|
2020
Q4 | $6.23M | Sell |
225,554
-95,611
| -30% | -$1.86M | ﹤0.01% | 3099 |
|
|
2020
Q3 | $4.51M | Sell |
321,165
-14,824
| -4% | -$276K | ﹤0.01% | 3194 |
|
|
2020
Q2 | $6.93M | Buy |
335,989
+312,427
| +1,326% | +$4.25M | ﹤0.01% | 2584 |
|
|
2020
Q1 | $178K | Buy |
+23,562
| New | +$264K | ﹤0.01% | 8834 |
|
|
2017
Q3 | – | Sell |
-55,426
| Closed | -$648K | – | 9862 |
|
|
2017
Q2 | $648K | Buy |
+55,426
| New | +$687K | ﹤0.01% | 6145 |
|
Other funds holding MYOV
Jeff Yass's MYOV Position: Q1 2023 in Review
Jeff Yass sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 25,615 shares — an estimated $691K sold.
Jeff Yass first reported a position in MYOV in Q2 2017 and held it in 13 quarters. The position peaked at $9.26M in Q4 2021. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.
- Jeff Yass reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
- Jeff Yass sold 25,615 Myovant Sciences Ltd. shares in Q1 2023, an estimated $691K.
- Jeff Yass first reported a position in Myovant Sciences Ltd. in Q2 2017 and held it in 13 quarters.
- Jeff Yass's Myovant Sciences Ltd. position peaked at $9.26M in Q4 2021.
- 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.
Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.